Orris

Blood transfusion in pathology

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

blood transfusion reaction hemolysis pathology

A clinical photograph displaying a side-by-side comparison of two whole blood units, illustrating the visual differences between normal and hemolyzed blood. The unit on the left represents a normal blood bag where distinct layering is visible: the upper portion contains clear, straw-colored (yellowish) plasma separated from the dark red sedimented red blood cells. The attached tubing segments on this bag also demonstrate clear, transparent plasma. In contrast, the unit on the right displays gross hemolysis, characterized by a uniform, dark reddish-black appearance throughout the entire bag. Crucially, the attached segments for the right-hand bag are filled with dark, opaque fluid instead of clear plasma, indicating the breakdown of red blood cells. This comparison serves as an educational tool for blood bank technicians and medical professionals to identify transfusion product contamination, thermal injury, or storage-related hemolysis during pre-issue inspections.

A clinical photograph displaying a side-by-side comparison of two whole blood units, illustrating the visual differences between normal and hemolyzed blood. The unit on the left represents a normal blood bag where distinct layering is visible: the upper portion contains clear, straw-colored (yellowish) plasma separated from the dark red sedimented red blood cells. The attached tubing segments on this bag also demonstrate clear, transparent plasma. In contrast, the unit on the right displays gross hemolysis, characterized by a uniform, dark reddish-black appearance throughout the entire bag. Crucially, the attached segments for the right-hand bag are filled with dark, opaque fluid instead of clear plasma, indicating the breakdown of red blood cells. This comparison serves as an educational tool for blood bank technicians and medical professionals to identify transfusion product contamination, thermal injury, or storage-related hemolysis during pre-issue inspections.

A multi-panel line graph illustrating the clinical course and treatment response of a patient with Paroxysmal Nocturnal Hemoglobinuria (PNH). The timeline spans from March 2009 to September 2012. The top panel monitors lactate dehydrogenase (LDH) levels (U/L), showing significant baseline hemolysis (fluctuating between 800-1600 U/L) that drops precipitously and stabilizes within normal limits following the initiation of Eculizumab in late 2011. The middle panel tracks serum creatinine (sCr) (mg/dL), indicating a gradual rise in renal dysfunction over time. The bottom panel displays hemoglobin (Hb) (g/dL) and platelet (PLT) (x10^4/μL) counts, highlighting periods of anemia and the frequency of blood transfusions (marked by vertical arrows). The figure also overlays pharmaceutical interventions, including dosages for prednisolone, methenolone, and eculizumab. This chart demonstrates the efficacy of terminal complement inhibition in controlling intravascular hemolysis and alleviating transfusion dependence in PNH patients.

A multi-panel line graph illustrating the clinical course and treatment response of a patient with Paroxysmal Nocturnal Hemoglobinuria (PNH). The timeline spans from March 2009 to September 2012. The top panel monitors lactate dehydrogenase (LDH) levels (U/L), showing significant baseline hemolysis (fluctuating between 800-1600 U/L) that drops precipitously and stabilizes within normal limits following the initiation of Eculizumab in late 2011. The middle panel tracks serum creatinine (sCr) (mg/dL), indicating a gradual rise in renal dysfunction over time. The bottom panel displays hemoglobin (Hb) (g/dL) and platelet (PLT) (x10^4/μL) counts, highlighting periods of anemia and the frequency of blood transfusions (marked by vertical arrows). The figure also overlays pharmaceutical interventions, including dosages for prednisolone, methenolone, and eculizumab. This chart demonstrates the efficacy of terminal complement inhibition in controlling intravascular hemolysis and alleviating transfusion dependence in PNH patients.

A medical pathophysiology diagram illustrating the oxidative stress cascade in Sickle Cell Disease (SCD) and its progression to vascular pathology. The diagram follows a vertical flow starting with a sickled red blood cell (RBC) undergoing HbS auto-oxidation and polymerization, leading to the generation of reactive oxygen species (ROS) such as H2O2, ferrylHb, and hemichromes. This triggers a central event of RBC hemolysis, characterized by membrane lipid oxidation, protein aggregation, and the release of pro-oxidant microparticles and L-arginase. Downstream pathways depict the systemic consequences, including the activation of platelets and the TLR4-linked inflammatory pathway, adhesion of SCD RBCs to endothelial cells and leukocytes, and a significant decrease in nitric oxide (NO) bioavailability. The lower section highlights the depletion of the antioxidant system and the oxidative modification of blood components into ADMA, AGEs, and ALEs. The cascade culminates in clinical manifestations such as vasoconstriction, endothelial dysfunction, and thrombosis, collectively summarized as SCD vascular pathology. This illustration is designed for advanced medical education regarding the molecular mechanisms of hematologic disorders.

A medical pathophysiology diagram illustrating the oxidative stress cascade in Sickle Cell Disease (SCD) and its progression to vascular pathology. The diagram follows a vertical flow starting with a sickled red blood cell (RBC) undergoing HbS auto-oxidation and polymerization, leading to the generation of reactive oxygen species (ROS) such as H2O2, ferrylHb, and hemichromes. This triggers a central event of RBC hemolysis, characterized by membrane lipid oxidation, protein aggregation, and the release of pro-oxidant microparticles and L-arginase. Downstream pathways depict the systemic consequences, including the activation of platelets and the TLR4-linked inflammatory pathway, adhesion of SCD RBCs to endothelial cells and leukocytes, and a significant decrease in nitric oxide (NO) bioavailability. The lower section highlights the depletion of the antioxidant system and the oxidative modification of blood components into ADMA, AGEs, and ALEs. The cascade culminates in clinical manifestations such as vasoconstriction, endothelial dysfunction, and thrombosis, collectively summarized as SCD vascular pathology. This illustration is designed for advanced medical education regarding the molecular mechanisms of hematologic disorders.

Summary : This image is a logo for "Transfusion Medicine," featuring stylized red blood cells and bold text. logo: TRANSFUSION MEDICINE Logo Elements : • Text: "TRANSFUSION MEDICINE" in uppercase, white font on a dark blue rectangular background. • Graphic: Multiple stylized red blood cells depicted to the left of the text, suggesting a medical or hematology theme. • Layout: The text is right-aligned with the blood cell graphics on the left, creating a balanced composition. • Colour palette: Dominant colours are dark blue (background for text) and red (blood cells), with white text for contrast. Dimensions & Placement : • Horizontal orientation. • Text box occupies the right half, blood cell graphics on the left. • No additional taglines or company names visible. Analysis : The logo visually communicates a focus on blood and transfusion medicine through the use of red blood cell imagery and clear, bold text. The colour scheme reinforces the medical theme and ensures high visibility and readability.

Summary : This image is a logo for "Transfusion Medicine," featuring stylized red blood cells and bold text. logo: TRANSFUSION MEDICINE Logo Elements : • Text: "TRANSFUSION MEDICINE" in uppercase, white font on a dark blue rectangular background. • Graphic: Multiple stylized red blood cells depicted to the left of the text, suggesting a medical or hematology theme. • Layout: The text is right-aligned with the blood cell graphics on the left, creating a balanced composition. • Colour palette: Dominant colours are dark blue (background for text) and red (blood cells), with white text for contrast. Dimensions & Placement : • Horizontal orientation. • Text box occupies the right half, blood cell graphics on the left. • No additional taglines or company names visible. Analysis : The logo visually communicates a focus on blood and transfusion medicine through the use of red blood cell imagery and clear, bold text. The colour scheme reinforces the medical theme and ensures high visibility and readability.

Finding Sources
Finding Sources
Reading File
Reading File
I have comprehensive, high-quality content from multiple authoritative sources. Let me now compile the full answer.

Blood Transfusion in Pathology

1. Blood Groups and Compatibility

Blood group antigens on red cell membranes (primarily the ABO and Rh systems) determine compatibility. ABO antigens are glycoproteins; naturally occurring IgM antibodies against absent ABO antigens already exist in plasma. The Rh(D) antigen is the most clinically significant Rh antigen - individuals lacking it (Rh-negative) can develop anti-D antibodies after exposure to Rh-positive cells (through transfusion or pregnancy). These acquired antibodies can cross the placenta and cause haemolytic disease of the fetus/newborn (hydrops fetalis).
Cross-matching precedes all transfusions:
  • Full crossmatch: ABO + Rh typing of donor and recipient, then mixing recipient serum with donor cells. Takes ~45 minutes.
  • Type-specific blood: ABO/Rh matched only, available in 10-15 minutes.
  • Emergency blood: Group O-negative (universal donor) to females, O-positive to males.

2. Blood Components Used in Transfusion

ComponentIndication
Packed Red Blood Cells (PRBCs)Anemia, active hemorrhage (threshold Hb <7-8 g/dL in stable patients; <9 g/dL with CAD)
PlateletsThrombocytopenia (<50,000/μL in active bleeding); not recommended empirically for patients on antiplatelets without thrombocytopenia
Fresh Frozen Plasma (FFP)Coagulopathy, elevated INR, liver disease, massive transfusion
CryoprecipitateLow fibrinogen; fibrinogen is essential to clot formation and stabilization
Prothrombin Complex Concentrate (PCC)Alternative to FFP in anticoagulant reversal
Whole BloodBeing re-explored in massive transfusion protocols
In massive transfusion, balanced resuscitation uses RBCs: Plasma: Platelets in a 1:1:1 ratio (approximating whole blood), combined with tranexamic acid (antifibrinolytic, given as early as possible for hyperfibrinolysis).

3. Hazards and Complications of Blood Transfusion

Reactions occur in approximately 1-2% of patients receiving transfusions. Complications are classified as:

Immunological Reactions

a) Acute Haemolytic Transfusion Reaction (AHTR)

  • Incidence: ~1:110,000 transfusions
  • Cause: ABO incompatibility - almost always due to human error (misidentification of patient, wrong specimen labelling, failure to check compatibility)
  • Mechanism: Recipient antibodies activate complement via the classical pathway → intravascular haemolysis → free haemoglobin release → renal tubular damage, DIC, shock
  • Clinical features: Fever, chills/rigors, anxiety, chest and back/flank pain, haemoglobinuria (dark urine), diffuse bleeding, oliguria/anuria, hypotension
  • Pathology at autopsy: Haemoglobinuric nephrosis - acute tubular necrosis with haemoglobin casts in renal tubules
  • Outcome: ~50% of ABO-incompatible transfusions have no adverse effect; 5% are fatal; death from anaphylaxis, renal failure, electrolyte imbalance, or DIC
Laboratory diagnosis:
  • Serum: ↑ haemoglobin, ↑ methemalbumin, ↓ haptoglobin (intravascular)
  • Serum: ↑ unconjugated bilirubin (extravascular)
  • Urine: haemoglobinuria, urobilinogen, red cell casts
  • Serology: positive direct Coombs (DAT) test, incompatible crossmatch, ↑ LDH
  • 2% red cell suspension may show agglutinates
Treatment: Stop transfusion immediately → IV saline + low-dose dopamine (maintain BP and urine output) → furosemide (increase renal blood flow) → FFP/cryoprecipitate/platelets/heparin for DIC
Normal vs hemolyzed blood units for transfusion comparison

b) Febrile Non-Haemolytic Transfusion Reaction (FNHTR)

  • Incidence: ~1:1,100 transfusions (most common reaction type)
  • Cause: In platelets - leukocyte-derived cytokines accumulate during storage; in RBCs - donor leukocytes interact with recipient white cell antibodies (graft-vs-host-type response)
  • Clinical features: Temperature rise ≥1°C or >38°C + chills/rigors within 4 hours of transfusion cessation
  • Management: Stop transfusion; supportive care; exclude more serious reaction
  • Prevention: Leukoreduction (leukodepletion) markedly reduces incidence

c) Allergic Transfusion Reaction

  • Incidence: ~1:1,200 transfusions
  • Cause: Sensitivity to donor plasma proteins (leukocytes, platelets, plasma components)
  • Features: Urticaria to anaphylaxis; eosinophilia may be present; IgA-specific antibodies found in IgA-deficient recipients reacting to donor IgA
  • Severe anaphylaxis: Rare; seen in IgA-deficient patients with anti-IgA antibodies

d) Transfusion-Related Acute Lung Injury (TRALI)

  • Definition: Non-cardiogenic pulmonary oedema (ARDS-like picture) within minutes to hours of transfusion of blood products (FFP > platelets > RBCs)
  • Incidence: 1:1,000 to 1:100,000; leading cause of transfusion-related mortality
  • Pathobiology (two mechanisms):
    1. Antibody-mediated: Donor HLA class I/II or neutrophil-specific antigen (NSA) antibodies bind recipient leukocytes → release of oxidative/non-oxidative products → pulmonary endothelial damage. HLA antibodies develop in multiparous female donors.
    2. Two-hit model: Pre-existing neutrophil priming (trauma, sepsis, surgery) + activation by bioactive lipids/cytokines from stored blood products → lung injury
  • Pathology: Alveolar filling with protein-rich fluid; increased microvascular permeability from pulmonary endothelial damage
  • Clinical: Hypoxia, bilateral pulmonary infiltrates on CXR, fever, hypotension; indistinguishable from ARDS/cardiogenic oedema
  • Prevention: Use of male or never-pregnant female donors for plasma-containing products; pathogen-reduction technologies

Non-Immunological Reactions

ComplicationMechanism / Notes
Circulatory overload (TACO)Volume excess → pulmonary oedema; distinguish from TRALI by raised BNP and response to diuretics
Coagulation defectsDilutional coagulopathy in massive transfusion; DIC in haemolytic reactions
HyperkalaemiaStored RBCs leak K⁺; risk with rapid/massive transfusion
HypocalcaemiaCitrate (anticoagulant in stored blood) chelates Ca²⁺; seen in massive/rapid transfusion
HypothermiaRapid transfusion of cold blood; lungs oedematous on autopsy if circulatory overload
Air embolismAir entering transfusion line; autopsy shows air in right ventricle
ThrombophlebitisAt venous access site
Bacterial infectionFaulty storage; more common with platelets (stored at room temperature)
Viral infectionsHepatitis B, Hepatitis C, HIV, CMV; markedly reduced by modern screening
Parasitic infectionsMalaria, toxoplasmosis (rare)
Iron overloadRepeated transfusions (e.g., thalassaemia); each unit of RBCs contains ~250 mg elemental iron → haemosiderosis
HyperfibrinolysisCommon in trauma/massive haemorrhage → treat with tranexamic acid

4. Classification of Blood Transfusion Hazards (Forensic/Pathology)

(From The Essentials of Forensic Medicine and Toxicology, 36th Ed.)
ImmunologicalNon-Immunological
Intravascular haemolysisCirculatory overload
Extravascular haemolysisCoagulation defects
Sensitivity to WBCs, platelets, plasma componentsHyperkalaemia
Citrate toxicity
Infections (syphilis, hepatitis, toxoplasmosis, AIDS)
Air embolism
Hypothermia
Rigors
Common clerical errors in transfusion:
  1. Clerical/labelling error (most common overall cause of ABO incompatibility)
  2. Confusing terminology ("group A serum" vs "anti-B serum")
  3. Failure to check bottle reference against lab compatibility report
  4. Similarly-named patients in the same ward

5. Forensic/Medicolegal Aspects

Samples to preserve in suspected fatal transfusion reaction:
  1. Sample of blood transfused
  2. Sample of recipient blood before and after transfusion
  3. At autopsy: kidneys, blood, urine
Cause of death in fatal reactions: anaphylaxis, renal failure, electrolyte imbalance, or circulatory overload
Autopsy findings:
  • Acute intravascular haemolysis: Haemoglobinuric nephrosis - acute tubular necrosis, haemoglobin casts in tubules
  • Circulatory overload: Pulmonary oedema (oedematous lungs)
  • Air embolism: Air in right ventricle

6. Transfusion Thresholds (Pathophysiology Context)

  • Stable patients without CAD: Transfuse when Hb <7-8 g/dL (restrictive strategy reduces mortality vs liberal strategy - supported by RCTs in GI bleeding)
  • Known/symptomatic CAD: Target Hb >9 g/dL
  • Portal hypertension bleeding: Monitor closely; overtransfusion worsens portal pressure and can increase bleeding
  • Platelets: Maintain >50,000/μL in active GI bleeding (ACG guidelines)
  • Massive transfusion protocol: RBCs:FFP:Platelets = 1:1:1 + cryoprecipitate for fibrinogen + tranexamic acid
Key sources: Bailey and Love's Short Practice of Surgery, 28th Ed. | Goldman-Cecil Medicine, International Ed. | The Essentials of Forensic Medicine and Toxicology, 36th Ed. | Rosen's Emergency Medicine, 10th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.